hide message

Welcome to the Resource Centre

We make it our mission to work with advocates in civil society, business and government to address inequalities of power, seek remedy for abuse, and ensure protection of people and planet.

Both companies and impacted communities thank us for the resources and support we provide.

This is only possible because of your support. Please make a donation today.

Thank you,
Phil Bloomer, Executive Director

Donate now hide message

You are being redirected to the story the piece of content is found in so you can read it in context. Please click the following link if you are not automatically redirected within a couple seconds:

Improving maternal health and access to contraceptives: Pharmaceutical companies’ contribution to MDG 5

Author: Access to Medicine Foundation, Published on: 9 April 2015

Pharmaceutical companies operationalise commitments to MDG 5 with a variety of initiatives. Ten of the world’s largest pharmaceutical companies are taking some action to improve access to maternal health and family planning, by making public commitments and/or implementing a range of initiatives. This includes five out of six companies with relevant products. All initiatives involve partners and the majority focus on local capacity building. With the Sustainable Development Goals due to be launched this year, this report can be used as a baseline for monitoring whether and how individual research-based pharmaceutical companies are working to improve access to maternal and reproductive health. Measuring progress against such targets is key for maintaining momentum and focus…[Refers to Astellas, Bayer, Daiichi Sankyo, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Novo Nordisk (part of Novo Group), Pfizer, Roche, Sanofi]

Read the full post here

Related companies: Bayer Daiichi Sankyo GlaxoSmithKline Johnson & Johnson Merck Novartis Novo Group Novo Nordisk (part of Novo Group) Pfizer Roche Sanofi